SCHEDULE 13G: Benjamin Weinstein Discloses 5.2% Stake in Precision Biosciences Inc.

Benjamin Weinstein has reported a beneficial ownership of 5.2% of Precision Biosciences Inc.'s common stock, totaling 395,489 shares, as of March 18, 2025.

Summary

• Benjamin Weinstein has filed a Schedule 13G with the SEC, disclosing beneficial ownership of common stock in Precision Biosciences Inc.
• Mr. Weinstein beneficially owns 395,489 shares of Precision Biosciences Inc. Common Stock, par value $0.000005 per share.
• This ownership represents 5.2% of the company's outstanding common stock.
• Mr. Weinstein holds sole voting power and sole dispositive power over all 395,489 shares.
• The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would significantly alter the company's perceived financial or operational performance, thus maintaining a neutral sentiment.

Positives

• The disclosure of a significant individual stake (5.2%) by Benjamin Weinstein may signal confidence in Precision Biosciences Inc.'s future prospects.

Risks

• The filing explicitly states that the securities were not acquired for the purpose of changing or influencing the control of the issuer, mitigating potential governance concerns related to this specific stake.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant individual shareholder's stake in the company.

Key Dates

Keywords

Precision Biosciences, Benjamin Weinstein, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Stock Ownership